Literature DB >> 27939129

Guillain Barré Syndrome is induced in Non-Obese Diabetic (NOD) mice following Campylobacter jejuni infection and is exacerbated by antibiotics.

J L St Charles1, J A Bell2, B J Gadsden1, A Malik3, H Cooke4, L K Van de Grift4, H Y Kim5, E J Smith2, L S Mansfield6.   

Abstract

Campylobacter jejuni is a leading cause of bacterial gastroenteritis linked to several serious autoimmune sequelae such as the peripheral neuropathies Guillain Barré syndrome (GBS) and Miller Fisher syndrome (MFS). We hypothesized that GBS and MFS can result in NOD wild type (WT) mice or their congenic interleukin (IL)-10 or B7-2 knockouts secondary to C. jejuni infection. Mice were gavaged orally with C. jejuni strains HB93-13 and 260.94 from patients with GBS or CF93-6 from a patient with MFS and assessed for clinical neurological signs and phenotypes, anti-ganglioside antibodies, and cellular infiltrates and lesions in gut and peripheral nerve tissues. Significant increases in autoantibodies against single gangliosides (GM1, GQ1b, GD1a) occurred in infected NOD mice of all genotypes, although the isotypes varied (NOD WT had IgG1, IgG3; NOD B7-2-/- had IgG3; NOD IL-10-/- had IgG1, IgG3, IgG2a). Infected NOD WT and NOD IL-10-/- mice also produced anti-ganglioside antibodies of the IgG1 isotype directed against a mixture of GM1/GQ1b gangliosides. Phenotypic tests showed significant differences between treatment groups of all mouse genotypes. Peripheral nerve lesions with macrophage infiltrates were significantly increased in infected mice of NOD WT and IL-10-/- genotypes compared to sham-inoculated controls, while lesions with T cell infiltrates were significantly increased in infected mice of the NOD B7-2-/- genotype compared to sham-inoculated controls. In both infected and sham inoculated NOD IL-10-/- mice, antibiotic treatment exacerbated neurological signs, lesions and the amount and number of different isotypes of antiganglioside autoantibodies produced. Thus, inducible mouse models of post-C. jejuni GBS are feasible and can be characterized based on evaluation of three factors-onset of GBS clinical signs/phenotypes, anti-ganglioside autoantibodies and nerve lesions. Based on these factors we characterized 1) NOD B-7-/- mice as an acute inflammatory demyelinating polyneuropathy (AIDP)-like model, 2) NOD IL-10-/- mice as an acute motor axonal neuropathy (AMAN)-like model best employed over a limited time frame, and 3) NOD WT mice as an AMAN model with mild clinical signs and lesions. Taken together these data demonstrate that C. jejuni strain genotype, host genotype and antibiotic treatment affect GBS disease outcomes in mice and that many disease phenotypes are possible.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Autoimmunity; Campylobacter jejuni; Guillain Barré Syndrome; Mouse models; Peripheral neuropathy

Mesh:

Substances:

Year:  2016        PMID: 27939129     DOI: 10.1016/j.jaut.2016.09.003

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  17 in total

Review 1.  Autoimmunity in 2016.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

2.  Induction of broadly reactive influenza antibodies increases susceptibility to autoimmunity.

Authors:  Jocelyn G Labombarde; Meenu R Pillai; Marie Wehenkel; Chun-Yang Lin; Rachael Keating; Scott A Brown; Jeremy Chase Crawford; David C Brice; Ashley H Castellaw; Alexandra H Mandarano; Clifford S Guy; Juan R Mejia; Carlessia D Lewis; Ti-Cheng Chang; Christine M Oshansky; Sook-San Wong; Richard J Webby; Mei Yan; Quan-Zhen Li; Tony N Marion; Paul G Thomas; Maureen A McGargill
Journal:  Cell Rep       Date:  2022-03-08       Impact factor: 9.995

3.  Th1/Th17-mediated Immunity and Protection from Peripheral Neuropathy in Wildtype and IL10-/- BALB/c Mice Infected with a Guillain-Barré Syndrome-associated Campylobacter jejuni Strain.

Authors:  Jean M Brudvig; Matthew M Cluett; Elizabeth U Gensterblum-Miller; James Chen; Julia A Bell; Linda S Mansfield
Journal:  Comp Med       Date:  2022-03-10       Impact factor: 1.565

Review 4.  Novel pathomechanisms in inflammatory neuropathies.

Authors:  David Schafflick; Bernd C Kieseier; Heinz Wiendl; Gerd Meyer Zu Horste
Journal:  J Neuroinflammation       Date:  2017-11-28       Impact factor: 8.322

5.  Transplanted human fecal microbiota enhanced Guillain Barré syndrome autoantibody responses after Campylobacter jejuni infection in C57BL/6 mice.

Authors:  Phillip T Brooks; Kelsey A Brakel; Julia A Bell; Christopher E Bejcek; Trey Gilpin; Jean M Brudvig; Linda S Mansfield
Journal:  Microbiome       Date:  2017-08-08       Impact factor: 14.650

6.  A novel mouse model of Campylobacter jejuni enteropathy and diarrhea.

Authors:  Natasa Giallourou; Gregory L Medlock; David T Bolick; Pedro Hqs Medeiros; Solanka E Ledwaba; Glynis L Kolling; Kenneth Tung; Patricia Guerry; Jonathan R Swann; Richard L Guerrant
Journal:  PLoS Pathog       Date:  2018-05-23       Impact factor: 6.823

7.  Campylobacter colonization is not associated with proventricular dilatation disease in psittacines.

Authors:  Holden Bulbow; Jing Wu; Debra Turner; Michael McEntire; Ian Tizard
Journal:  Vet Med (Auckl)       Date:  2017-08-03

8.  Multi-Omics Approach Reveals the Potential Core Vaccine Targets for the Emerging Foodborne Pathogen Campylobacter jejuni.

Authors:  Hengchun Cao; Hanxiao Xu; Chunhui Ning; Li Xiang; Qiufang Ren; Tiantian Zhang; Yusen Zhang; Rui Gao
Journal:  Front Microbiol       Date:  2021-06-24       Impact factor: 5.640

9.  Whole Genome Sequencing and Multiplex qPCR Methods to Identify Campylobacter jejuni Encoding cst-II or cst-III Sialyltransferase.

Authors:  Jason M Neal-McKinney; Kun C Liu; Karen C Jinneman; Wen-Hsin Wu; Daniel H Rice
Journal:  Front Microbiol       Date:  2018-03-16       Impact factor: 5.640

10.  Gut Microbiota Confers Resistance of Albino Oxford Rats to the Induction of Experimental Autoimmune Encephalomyelitis.

Authors:  Suzana Stanisavljević; Miroslav Dinić; Bojan Jevtić; Neda Đedović; Miljana Momčilović; Jelena Đokić; Nataša Golić; Marija Mostarica Stojković; Đorđe Miljković
Journal:  Front Immunol       Date:  2018-05-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.